
-
RAPT Therpaeutics NasdaqGM:RAPT RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Location: 561 Eccles Avenue, South San Francisco, CA, 94080, United States | Website: https://www.rapt.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-52.37M
Cash
179.3M
Avg Qtr Burn
-27.16M
Short % of Float
10.11%
Insider Ownership
0.42%
Institutional Own.
99.44%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RPT904 Details Food allergy | Phase 2b Initiation | |
Tivumecirnon / FLX475 (CCR4 antagonist) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Update | |
Zelnecirnon/ RPT193 (CCR4 antagonist) Details Asthma, Lung disease | Failed Discontinued | |
Zelnecirnon / RPT193 (CCR4 antagonist) Details Atopic dermatitis | Failed Discontinued |